GlaxoSmithKline News and Research

RSS

Cambridge Pharmaceutical Cryo-EM Consortium formed by FEI, five pharmaceutical companies, the Medical Research Council and the University of Cambridge

FEI (NASDAQ: FEIC) has partnered with five pharmaceutical companies: Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics, and UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB); and the University of Cambridge’s Nanoscience Centre, to form the “Cambridge Pharmaceutical Cryo-EM Consortium,” which is the first of its kind worldwide.

From Thermo Fisher Scientific – Electron Microscopy Solutions 4 Apr 2016

Johns Hopkins scientists develop antibody to curb lung tumor cell growth, breast cancer metastasis

Johns Hopkins scientists report they have developed an antibody against a specific cellular gateway that suppresses lung tumor cell growth and breast cancer metastasis in transplanted tumor experiments in mice, according to a new study published in the February issue of Nature Communications.

17 Mar 2016

WRAIR researchers publish results from Plasmodium vivax malaria vaccine study

Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.

27 Feb 2016

Two investigational Ebola vaccines well-tolerated in Phase 2 clinical trial

Two investigational vaccines designed to protect against Ebola virus disease were well-tolerated and induced an immune response among 1,000 vaccinated participants in the Phase 2 randomized, placebo-controlled clinical trial called PREVAIL I.

25 Feb 2016

FDA approves Lannett's ANDA for Sumatriptan Nasal Spray USP

Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray USP, 5 mg/spray and 20 mg/spray, the therapeutic equivalent to the reference listed drug Imitrex Nasal Spray, of GlaxoSmithKline.

22 Feb 2016

New visiongain report on Zika virus

What can be expected as the Zika outbreak progresses? Which areas are going to be the most affected? This visiongain report discusses the future direction of the Zika virus outbreak and the implications of its spread. It also discussed the infectious disease diagnostics market and the global human vaccines market, both of which are forecast to 2026.

22 Feb 2016

Mylan announces FDA's acceptance of ANDA filing for generic Advair Diskus

Mylan N.V. today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted for filing by the U.S. Food and Drug Administration.

22 Feb 2016

Clinical study shows new Ebola vaccine stimulates strong immune responses in adults

A clinical trial of a new Ebola vaccine (ChAd3-EBO-Z) that resulted from an unprecedented global consortium assembled at the behest of the World Health Organization has found that it is well tolerated and stimulates strong immune responses in adults in Mali, West Africa and in the US, according to a study published in the latest issue of the journal Lancet Infectious Disease.

19 Nov 2015

NIAID launches major initiative to advance novel approaches to treat, prevent HIV infections

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, launched a major initiative to advance novel approaches to treat and prevent HIV infections based on broadly neutralizing antibodies (bNAbs) today.

19 Nov 2015

Nucala (mepolizumab) approved for treatment of asthma patients

The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.

5 Nov 2015

Denator forms a new Scientific Advisory Board

Denator AB has announced that a new external expert advisory board has been formed. Karsten Fjärstedt, recently appointed as CEO comments, “It is a great honor for me to be entrusted to lead Denator forward in this new phase of development. With a pipeline of new exciting business opportunities and a strong Scientific Advisory Board (SAB) I am looking forward to realizing the full potential of the company technology”.

3 Nov 2015

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

Researchers use cutting edge genomic methods to explain protective effects of malaria vaccine candidate

An international team led by researchers from the Broad Institute of MIT and Harvard, the Harvard T.H. Chan School of Public Health, and Fred Hutchinson Cancer Research Center have used cutting edge genomic methods to uncover key biological insights that help explain the protective effects of the world's most advanced malaria vaccine candidate, RTS,S/AS01 (RTS,S).

22 Oct 2015

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.

9 Oct 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

Reducing hospital readmissions through Transitional Care: an interview with Rani Khetarpal

Services provided to a patient whose medical and/or psychosocial problems require moderate or high-complexity medical decision making during transitions in care from an inpatient setting, partial hospital, observation status in a hospital, or skilled nursing facility to the patient’s community setting.

27 Aug 2015

New article proposes creation of $2 billion global vaccine-development fund to prevent infectious diseases

Ebola is a preventable disease, and yet a safe and effective vaccine has not been deployed. As with many vaccines, financial barriers persist: pharmaceutical companies see high costs with limited market potential, and government support is lacking. But there may be a solution to this vaccine crisis with the ability to save at-risk populations, according to a perspective piece written by physicians based at Princeton University, University of Pennsylvania and the Wellcome Trust.

4 Aug 2015

New white paper provides overview of factors that drive vaccination underutilization in older adults

Today the nonprofit Alliance for Aging Research released a white paper, Our Best Shot: Expanding Prevention through Vaccination in Older Adults, that provides a comprehensive overview of the factors that drive vaccination underutilization in seniors and offers recommendations on how industry, government, and health care experts can improve patient compliance.

30 Jul 2015

New consortium aims to develop precision medicines for globally devastating diseases

An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.

29 Jul 2015

United Therapeutics’ revenues increase by $24.4 million in second quarter 2015

United Therapeutics Corporation today announced its financial results for the second quarter ended June 30, 2015. "Orenitram sales grew nearly 300% as compared to the second quarter of 2014 when the product was first launched," said Roger Jeffs, Ph.D., United Therapeutics' President and Co-Chief Executive Officer.

28 Jul 2015

GlaxoSmithKline News and Research

Cambridge Pharmaceutical Cryo-EM Consortium formed by FEI, five pharmaceutical companies, the Medical Research Council and the University of Cambridge

Johns Hopkins scientists develop antibody to curb lung tumor cell growth, breast cancer metastasis

WRAIR researchers publish results from Plasmodium vivax malaria vaccine study

Two investigational Ebola vaccines well-tolerated in Phase 2 clinical trial

FDA approves Lannett's ANDA for Sumatriptan Nasal Spray USP

New visiongain report on Zika virus

Mylan announces FDA's acceptance of ANDA filing for generic Advair Diskus

Clinical study shows new Ebola vaccine stimulates strong immune responses in adults

NIAID launches major initiative to advance novel approaches to treat, prevent HIV infections

Nucala (mepolizumab) approved for treatment of asthma patients

Denator forms a new Scientific Advisory Board

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Researchers use cutting edge genomic methods to explain protective effects of malaria vaccine candidate

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Reducing hospital readmissions through Transitional Care: an interview with Rani Khetarpal

New article proposes creation of $2 billion global vaccine-development fund to prevent infectious diseases

New white paper provides overview of factors that drive vaccination underutilization in older adults

New consortium aims to develop precision medicines for globally devastating diseases

United Therapeutics’ revenues increase by $24.4 million in second quarter 2015

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News